LC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
==== Cover-up allegations ==== Fonterra notified the New Zealand government on 5 September and three days later, Prime Minister Helen Clark had Beijing officials alerted directly. News reports began circulating in China on 9 September, and the news was broken internationally by Reuters the following day. The state-controlled media report did not initially identify the company involved. Posts on Chinese social portal Tianya named Sanlu as the culprit, which Sanlu denied. According to a State Council investigation, Sanlu had known about infants made sick by its products as early as December 2007, but no testing was performed until June 2008. It said leading government officials in Shijiazhuang city had failed to report the contamination to provincial and state authorities (until 9 September) in violation of rules on reporting major incidents involving food safety. According to the People's Daily, on 2 August, Sanlu asked the Shijiazhuang city government to assist them in controlling the media's reporting of the recall. According to accounts confirmed by media reports and health officials, the company tried to buy off critics and cover up the contamination. In a memo dated 11 August, Beijing-based public relations agency Teller International advised Sanlu to seek cooperation with major search engines to censor negative information. The agency reportedly had repeatedly contacted key account staff at Baidu and proposed a ¥3 million (US$440,000) budget to screen all negative news.
Some molecular biology research suggests that GAHT induces a "unique molecular profile" with potential relevance to the recipient's immune system, or (in)susceptibility to certain health conditions (which are sometimes sexually dimorphic in people); one 2022 analysis found that GAHT (both feminizing and masculinizing) influenced gene expression. The study's lead author stated that they observed "changes [to] the epigenetic landscape of DNA" in some regions but not others, and that of the observed "epigenetic changes in regions of DNA that were distinct between sexes before hormone therapy, these regions consistently shifted towards the profile of the affirmed gender after 12 months of hormone therapy." A 2023 molecular study on the breast tissue of transgender men found that adding androgens induced such changes, appearing to silence genes across the breast tissue, including a suppression of genes linked to breast cancer.
=== Accolades === Greek Prime Minister George Papandreou ended the Cabinet meeting on 25 January 2011 by saying: "The news that the film Dogtooth by Yorgos Lanthimos is nominated for Best Foreign Language Film goes far beyond the world of cinema, arts and culture. It concerns the whole country, its people, the new generation of artists who follow the motto 'Yes, we can do it' during difficult times." He continued, "I won't say that the news shows that miracles happen, because the success of Yorgos Lanthimos is based on hard work, talent and his endless potential. Features that characterize the creative forces which lead Greece to a new era; forces which deserve our support and they will have it. Bravo Yorgos." The Greek Film Committee unanimously chose Dogtooth to represent Greece at the Oscars.
=== Potential risks === As BLCO contains materials like vanadium, nickel and PAH, those tend to be harmful and disturb possibility of antioxidant. Heavy metals are necessary in metabolic process of creatures; however, they are the causes of physiological stress at the same time. Pollution problems by oil spills like soils contamination are continuous and prevalent, putting severe health and environmental threats. The pollutants can gradually accumulate in food chains and interrupt biological actions of creatures. Petroleum contaminants are pernicious to nature and moreover, their hydrocarbon elements which are mutagenic and causing cancers, entail immunomodulatory impacts on humans and organisms as well. The symptoms of risks can appear immediately or emerge after some time.
== Background == Chinese Communist Party general secretary Xi Jinping and United States president Donald Trump held their first meeting during Trump's second presidency at the Busan Summit on 30 October 2025. At the meeting, Trump announced plans to visit China in April of the following year and invited Xi to visit the United States at an appropriate time. The state visit was planned for the first week of April, but the meeting was postponed to May due to the 2026 Iran war. On 25 March, The White House announced Trump's visit would last from 12 to 15 May. In the lead-up to the summit, regional security concerns regarding the conflict with Iran became a key diplomatic focus. On 16 April, Defense Secretary Pete Hegseth announced that Beijing had provided high-level assurances to the White House that it would not send weapons to Iran, explicitly ruling out the potential transfer of surface-to-air missiles to the Iranian military. Hegseth attributed this breakthrough to the "strong and direct relationship" between President Trump and Xi Jinping, noting that the assurances were vital for the upcoming meeting in Beijing. U.S. secretary of state Marco Rubio met on 13 February with Wang Yi, director of the Office of the Central Foreign Affairs Commission and foreign minister. The two sides discussed President Donald Trump's planned visit to China. On 30 April, Wang held a phone call with Rubio to conduct preliminary communication regarding subsequent head-of-state diplomacy. Steve Daines led the first bipartisan U.S.
Sources: en.wikipedia.org
Point-of-care ultrasound (POCUS) may be useful in the diagnosis of NF when MRI and CT are unavailable. It can also help rule out diagnoses that mimic earlier stages of NF, including deep vein thrombosis (DVT), superficial abscesses, and venous stasis. Linear probes are generally preferred for the assessment, especially in the extremities. Findings characteristic of NF include abnormal thickening, air, or fluid in the subcutaneous tissue. This can be summarized as the mnemonic "STAFF" (Subcutaneous irregularity or Thickening, Air, and Fascial Fluid). The official diagnosis of NF using ultrasound requires "the presence of BOTH diffuse subcutaneous thickening AND fascial fluid more than 2 mm." Gas in the subcutaneous tissue may show "dirty acoustic shadowing." However, similar to other imaging modalities, the absence of subcutaneous free air does not definitively rule out a diagnosis of NF, because this is a finding that often emerges later in the disease process. Of note, the quality and accuracy of POCUS are highly user-dependent. It may also be difficult to visualize NF over larger areas, or if there are many intervening layers of fat or muscle. It is still unclear whether POCUS improves the speed of diagnosis of NF or if it reduces the time to surgical intervention as a whole.
2006 – Ada Yonath "for ingenious structural discoveries of the ribosomal machinery of peptide-bond formation and the light-driven primary processes in photosynthesis. 2022 – Bonnie L. Bassler and Carolyn R. Bertozzi "for their seminal contributions to understanding the chemistry of cellular communication and inventing chemical methodologies to study the role of carbohydrates, lipids, and proteins in such biological processes."
The term Western blot was given by W. Neal Burnette in 1981, although the method, but not the name, was independently invented in 1979 by Jaime Renart, Jakob Reiser, and George Stark, and by Harry Towbin, Theophil Staehelin, and Julian Gordon at the Friedrich Miescher Institute in Basel, Switzerland. The Towbin group also used secondary antibodies for detection, thus resembling the actual method that is almost universally used today. Between 1979 and 2019 "it has been mentioned in the titles, abstracts, and keywords of more than 400,000 PubMed-listed publications" and may still be the most-used protein-analytical technique.
== History == While the use of PEDs has expanded in recent times, the practice of using substances to improve performance has been around since the Ancient Olympic Games. In the Olympic Games of 668 BC, Charmis had consumed a diet consisting of dried figs which was thought, at the time, to be a significant factor in winning the 200-yard stade race. Ancient Greek athletes at the time also incorporated substances such as wine and brandy into their training routines. Stimulants derived from plants (e.g., Cola nitida, Bufotenin, etc.) were used by the Roman gladiators to overcome injuries and fatigue. In the late 19th century as modern medicine and pharmacology were developing, PEDs saw an increase in use. Supplements were now exclusively being used to enhance muscular work capacity. The main substances being used included alcoholic drinks, caffeine, and mixtures created by the athletic trainers (e.g., strychnine tablets made of cocaine and brandy). In the 20th century, testosterone was isolated and characterized by scientists. In 1941, the first record of synthesized testosterone use occurred when a horse was given testosterone which successfully improved its race performance. Sports trainers soon after began advocating for testosterone use. Images of bodybuilders with massive muscles began circulating which further perpetuated a desire among athletes to use testosterone. In 1967, the first prohibited substance list and anti-doping measures were implemented at the 1968 Olympics. In the 1980s, the main PEDs were cortisone and anabolic steroids.
Pianist Bill Payne of Little Feat contributed keyboards for the first time, beginning a decades-long collaboration that included many recording sessions and even a two-week stint touring with the band in early 1974. A string of hits followed, including Johnston's "Long Train Runnin'" and "China Grove", from the 1973 album The Captain and Me. Other noteworthy songs on the album were Simmons' country-ish ode "South City Midnight Lady" and the explosive, hard rocking raveup "Without You", for which the entire band received songwriting credit. Onstage, the latter song sometimes stretched into a 15-minute jam with additional lyrics completely ad-libbed by Johnston. A 1973 appearance on the debut episode of the television music variety show Don Kirshner's Rock Concert featured one such performance of the tune. In the midst of recording sessions for their next album, 1974's What Were Once Vices Are Now Habits, and rehearsals for a 1973 fall tour, Hossack abruptly departed the band, citing burnout from constant touring. Drummer, songwriter, and vocalist Keith Knudsen (who previously drummed for Lee Michaels of "Do You Know What I Mean" fame) was recruited in September 1973 and left with the Doobies on a major tour a few weeks later (Hossack subsequently replaced Knudsen in the band Bonaroo, which served as an opening act for the Doobies shortly thereafter). Both Hossack's drums and Knudsen's voice are heard on What Were Once Vices Are Now Habits.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.